GlassScriptPhysician profile
Ismael A Matus
NPI 1538118070
$26,567.89
in general payments reported to CMS, 2019-2025
14 companies · $9,894 in 2025
The $9,894 reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $105 · 2022: $1,282 · 2023: $12K · 2024: $2,696 · 2025: $9,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $3,795 · Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,790.00 |
| Travel and Lodging | $3,794.54 |
| Food and Beverage | $1,479.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $20,523.44 | 2021-2025 | Monarch, Monarch Platform |
| Intuitive Surgical, INC. | $2,234.88 | 2024-2025 | |
| Noah Medical Corporation | $1,757.40 | 2023-2025 | Galaxy |
| Medical Device Business Services, INC. | $647.15 | 2023 | Monarch |
| Pinnacle Biologics, INC | $428.86 | 2022-2025 | Photofrin |
| Galvanize Therapeutics, INC | $379.66 | 2024-2025 | Aliya System |
| Pulmonx Corporation | $165.50 | 2020-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Boston Scientific Corporation | $165.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $69.71 | 2021-2025 | Imfinzi |
| Covidien LP | $58.73 | 2020 | |
| Merck Sharp & Dohme LLC | $57.52 | 2024-2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $40.57 | 2025 | Enhertu, Datroway |
| Caris Mpi, INC. | $26.44 | 2025 | Mi Cancer Seek |
| Olympus America INC. | $12.90 | 2023 | Visiglide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismael Matus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.